Company: STAA
Filing Date: 2025-09-22
Form Type: DEFA14A
Source: 0001193125-25-210031
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-09-22
Form: DEFA14A
Chunk 2
---
 fee that would be payable to Alcon if STAAR terminates the Alcon merger agreement to accept a superior proposal received after September 19, 2025. The $28.00 per share all-cashconsideration in the Alcon merger agreement provides STAAR stockholders with compelling, certain, and immediate cash value at a significant premium across multiple measures, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the agreement being announced) and a 59% premium to STAAR’s 90-dayvolume weighted average price as of that date. Broadwood is asking STAAR stockholders to forfeit the all-cash,premium value provided by the Alcon merger agreement and instead underwrite the significant risks inherent in STAAR as a standalone company. If the transaction is not approved, STAAR expects stockholders will be exposed to significant value destruction as compared to the $28 per share merger value. The Company’s stock was trading at $18.49 prior to the announcement of the agreement, and preliminary third quarter trends signal that the business challenges which have been adversely impacting STAAR’s financial results are continuing. STAAR’s stockholders are encouraged to reject Broadwood’s flawed and misleading claims. The STAAR Board of Directors strongly recommends STAAR stockholders vote “FOR” the merger proposal on the WHITE proxy card TODAY. Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: (877) 750-8233 (toll-free) |

| • |     | For banks and brokerage firms: (212) 750-5833 |

About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer ®Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL ™product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3